Home / Biotechnology / Biotechnology: Circulating Tumor Cells (CTC) Technologies

Biotechnology: Circulating Tumor Cells (CTC) Technologies

Published: Apr 2014 | No Of Pages: 384 | Published By: RI Technologies

This report on Circulating Tumor Cells (CTC) Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC industry, covering more than 150 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific with 53 exclusive graphically represented exhibits.

The biggest technical challenge is CTC detection despite the continued development of many new technologies. The key need is for a technology that will detect the real metastasis-initiating CTC which in turn will trigger distant metastases. This may be a combination of complementary technologies or even several technologies optimized for specific tumor types. CTC enrichment depends on the different properties of CTCs that distinguish them from the surrounding normal hematopoietic cells; physical properties; and biological properties. Most of the current technologies are still based on epithelial cell adhesion molecule (EpCAM) expression. New emerging technologies may try to capture EpCAM-negative CTCs. Circulating Tumor Cells (CTCs) are assuming importance as a biomarker for companion diagnostics and early detection for cancer treatment. There are many unmet needs in cancer drug development. Studying of tumor clusters, cell circulation, assessing and correlating types of tumors with their functionalities are vital aspects of CTC studies. Hundreds of clinical studies testify the requirement of detection and molecular characterization of CTCs. Risk estimation, therapy monitoring, identification of targets, and understanding metastatic developments are essential research areas. CTCs are known to represent the biology of cancer, and high counts of CTC lead to negative prognosis. Phenotyping and genotyping CTC and further studies will reveal whether CTC can be used for directing general or targeted anti-cancer therapy.

1. SCOPE AND METHODOLOGY

2. REPORT SYNOPSIS
2.1 Circulating Tumor Cells (CTC) Technologies – Introduction
2.2 Circulating Tumor Cells (CTC) Technologies – Timeline
Biomarkers
CTC as a Biomarker
Process of Metastatic Development, CTCs and Cancer Stem Cells
CTCs in Blood and DTCs in Bone Marrow
Circulating Tumor Cells and Their Clinical Significance
Detection of CTCs and its Significance
Epithelial Mesenchymal Transition
Technologies for Isolation and Characterization of CTCs
CTC and Prostate Cancer
CTC in Breast Cancer
CTCs in Ovarian Cancer
CTC Diagnosis & Prognosis
CTCs as Therapy Response Marker
2.3 Segmentation
Exhibit 1. Segmentation of Global CTC Technologies Market by Cancer Type and by Function
2.4 CTC Technologies - Global Market Analysis
Exhibit 2. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Billion (Graphical Representation Included)
Exhibit 3. List of Major Global Companies – CTC Technologies

3. MARKET DYNAMICS
3.1 Global CTC Technologies Market
Exhibit 4. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
Exhibit 5. CTC Technologies – Global Market Shares (2010 & 2015) for North America, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
Exhibit 6. Circulating Tumor Cell - Global Market Analysis (2010 - 2020) for Per Test Cost, Number of Tests and Cancer Incidence
Exhibit 7. List of Product/Technologies for CTC Analysis
Exhibit 8. Cancer Type and Respective Detection Methods and Markers
3.2 North American CTC Technologies Market
Exhibit 9. CTC Technologies – North American Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 10. CTC Technologies – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 11. Cancer Care – National Cost (2010) by Cancer Site in US$ Billion
Exhibit 12. Cancer Care - Annual Costs (2010) in US$
Exhibit 13. CTC Technologies - Major Organizations in the United States
3.3 European CTC Technologies Market
Exhibit 14. CTC Technologies – European Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 15. CTC Technologies - Major Organizations in the United Kingdom
Exhibit 16. CTC Technologies - Major Organizations in Germany
Exhibit 17. CTC Technologies - Major Organizations in France
Exhibit 18. CTC Technologies - Major Organizations in Switzerland
Exhibit 19. CTC Technologies - Major Organizations in Rest of Europe
3.4 Asia-Pacific CTC Technologies Market
Exhibit 20. CTC Technologies – Asia Pacific Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 21. CTC Technologies - Major Organizations in Japan
Exhibit 22. CTC Technologies - Major Organizations in India
Exhibit 23. CTC Technologies - Major Organizations in Rest of Asia Pacific
3.5 Rest of World CTC Technologies Market
Exhibit 24. CTC Technologies – Rest of World Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 25. CTC Technologies - Major Organizations in Israel
3.6 CTC Technologies Providers – Competitor Profiles
Abnova Corporation (Taiwan)
Affymetrix, Inc. (USA)
ApoCell, Inc (USA)
AVIVA BioSciences Corporation (USA)
BioCep Ltd. (Israel)
CytoTrack Aps (Denmark)
DTU Fotonik (Denmark)
Epic Sciences, Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Greiner Bio-One GmBH (Germany)
Invitrogen Corporation (USA)
Miltenyi Biotec, Inc. (USA)
On-Q-ity (USA)
Paterson Institute for Cancer Research (UK)
Quest PharmaTech, Inc. (Canada)
R.G.C.C. International GmbH (Switzerland)
ScreenCell (France)
TeloVISION, LLC (USA)
Veridex LLC (USA)
More…..
3.7 Significant Market Developments
Revised Coding and Payment Rates Likely for CTC Testing
Epic Sciences Enters into Partnerships with Six Pharma Cos.
Cynvenio Biosystems Solution for Sequencing Circulating Tumor Cells Isolated from Whole Blood
Affymetrix Completely Acquires eBioscience Holding Company
Fluxion Biosciences Partners with Rubicon Genomics for CTC Analysis
BioView Enters into Worldwide Commercial CTC Collaboration with ScreenCell
Fluxion Biosciences Collaborates with Stanford University School of Medicine for Developing New Technique to Analyze CTCs
TeloVISION LLC Partners with Purdue Research Park to Develop Low Cost Diagnostic Products
IVDiagnostics Establishes a New Office in Northwest Indiana
COMET-1 Pivotal Trial Initiated by Exelixis for Advanced Prostate Cancer
More…….
3.8 CTC Technologies - Analysis by Cancer Type
Exhibit 26. CTC Technologies by Type – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prostate Cancer, Breast Cancer and Other (Graphical Representation Included)
Exhibit 27. CTC Technologies by Type – Global Market Shares (2010 & 2015) for Prostate Cancer, Breast Cancer and Other (Graphical Representation Included)
3.8.1 Prostate Cancer
3.8.1 (I) Global Market for CTC Technologies in Prostate Cancer
Exhibit 28. CTC Technologies in Prostate Cancer – Global Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.8.1 (II) United States Market for CTC Technologies in Prostate Cancer
Exhibit 29. CTC Technologies in Prostate Cancer – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 30. List of Major Companies in CTC Technologies for Prostate Cancer
3.8.2 Breast Cancer
3.8.2 (I) Global Market for CTC Technologies in Breast Cancer
Exhibit 31. CTC Technologies in Breast Cancer – Global Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.8.2 (II) United States Market for CTC Technologies in Breast Cancer
Exhibit 32. CTC Technologies in Breast Cancer – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 33. List of Major Companies in CTC Technologies for Breast Cancer
3.8.3 Other Cancers
3.8.3 (I) Global Market for CTC Technologies in Other Cancers
Exhibit 34. CTC Technologies in Other Cancer – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.8.3 (II) United States Market for CTC Technologies in Other Cancers
Exhibit 35. CTC Technologies in Other Cancer – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.9 Analysis by Function
Exhibit 36. CTC Technologies by Function – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prognostics, Diagnostics and Therapy Management (Graphical Representation Included)
Exhibit 37. CTC Technologies by Function – Global Market Shares (2010 & 2015) for Prognostics, Diagnostics and Therapy Management (Graphical Representation Included)
3.9.1 Diagnostics
3.9.1 (I) Global Market for CTC Technologies in Diagnostics
Exhibit 38. CTC Technologies in Diagnostics – Global Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.9.1 (II) United States Market for CTC Technologies in Diagnostics
Exhibit 39. CTC Technologies in Diagnostics – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 40. Novel Methods for Circulating Tumor Cell Identification and Main Conclusion(s)
Exhibit 41. List of Major Companies in CTC Technologies for Diagnostics
3.9.2 Prognostics
3.9.2 (I) Global Market for CTC Technologies in Prognostics
Exhibit 42. CTC Technologies in Prognostics – Global Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.9.2 (II) United States Market for CTC Technologies in Prognostics
Exhibit 43. CTC Technologies in Prognostics – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 44. Clinical Studies Evaluating Circulating Tumor Cells as a Prognostic Tool
Exhibit 45. CTC Enrichment Methods
Exhibit 46. List of Major Companies in CTC Technologies for Prognostics
3.9.3 Therapy Management
3.9.3 (I) Global Market for CTC Technologies in Therapy Management
Exhibit 47. CTC Technologies in Therapy Management – Global Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
3.9.3 (II) United States Market for CTC Technologies in Therapy Management
Exhibit 48. CTC Technologies in Therapy Management – United States Market Estimations and Predictions (2010-2020) in US$ Million (Graphical Representation Included)
Exhibit 49. List of Major Companies in CTC Technologies for Therapy Management
3.10 Circulating Tumor Cells (CTC) Technologies – Market Outlook

4. PRODUCT/TECHNOLOGY RESEARCH
Circulating Tumor Cells (CTCs) – Key Observations
CTC Detection
The Hampering Facts
CTC Detection – Molecular Targets
CTC Enumeration
Exhibit 50. Novel Methods for Circulating Tumor Cell Identification and Main Conclusion(s)
CTC Enrichment
Exhibit 51. CTC Enrichment Methods
CTC Capture
CTC Isolation
Microfluidic Devices
CTCs and Cancer Stem Cells (CSCs)
Signaling Pathways
Surface Markers
Cancer Biomarkers
Tumor Marker
Cells as Biomarkers
Circulating Tumor Cells (CTCs) – Cancer Biomarkers
Functions of Biomarkers
Metronomic Chemotherapy for Cancer Treatment
Dispersal of Tumor Cells
Biology of Circulating Tumor Cells
Potential and Proliferative activity of Circulating Tumor Cells
CTCs and Epithelial Marker Genes
CTCs and Mesenchymal Transition
Stem Cell-like phenotype of CTCs
Changed Geno/Phenotype of CTCs when compared to Primary Tumor
Epithelial Mesenchymal Transition
Presence of CTCs in Epithelial Mesenchymal Transition and Disseminated Disease
Mesenchymal and Cancer Stem Cells
qPCR Expression Markers
Characterization of Protein Expression and Signaling in CTCs
Significance of Circulating Tumor Cells
Detection of CTCs and its Significance
CTC-Receptors
Major Causes of Metastasis
Cancer
Progesterone receptor Positive
HER-2 Positive Receptor
Triple Negative Type of Tumor
Mice models for CTC studies
CTC Count Prominence
Recent Technique on Cancer Prognosis
Immunofluorescent Staining Technique
FAST scanning
SERS Technology
CellSearch® System
Biochip Platforms
Photoacoustic Spectroscopy
Immunomagnetic Separation
Immunohistochemistry
CISH Technique
FISH Technique
Nanotechnology
Tagged- Amplicon Sequencing Technique
4.1 CTC Technologies
Techniques for Detection and Manipulation
Function-Based Methods
Nonfunction-Based Techniques
In Vivo CTC Manipulation Techniques
Challenges to In Vivo Manipulation Devices
Advanced CTC Detection Technologies Based on Genomics
4.2 CTC and Cancer Type
Introduction
Breast Cancer Therapy using Circulating Tumor Cells
CTC found in Early Metastasis
CTC Detection Methods
CTCs as a Biomarker in Advanced Breast Cancer
Detection of CTCs in Prostate & Colorectal Cancers
CTCs in Ovarian Cancer
Exhibit 52. Cancer Type and Respective Detection Methods and Markers
CTC Diagnosis and Prognosis
Circulating Tumor Cell based PSA as a Biomarkers in Prostate Cancer Prognosis
Exhibit 53. Clinical Studies Evaluating Circulating Tumor Cells as a Prognostic Tool
CTCs as Therapy Response Marker
CTCs in Custom-Made Medicine
4.3 Circulating Tumor Cells (CTC) Technologies - Research Briefs
Presence of Disseminated Tumor Cells after Neoadjuvant Therapy for Locally Advanced Breast Cancer Indicates Poor Survival
DETECT Study initiated for In-Depth Understanding of the Prominence of Circulating Tumor Cells in Metastatic Breast Cancer Patients
Hepatocellular Carcinoma and CTCs – Methods used for Detection, Clinical Consequences and Future Prospects
CTCs in Metastatic Colorectal Cancer –A Challenge to Researchers
A Study on Circulating Tumor Cells in Non-Metastatic Breast Cancer
CTCs for the Prediction of PFS (Progression-Free Survival) and OS (Overall Survival) in Patients with Relapsed/Recurrent Ovarian Cancer
CTCs in Breast Cancer – Challenges of Molecular Characterization and Promise of Customized Treatment
University of Texas MD Anderson Cancer Center Develops a Method for Predicting CTCs in the Early Stage Breast Cancer
Secreted Vesicles Assist the Spread of Cancer in the Body
More…..

5. CORPORATE DIRECTORY

6. PATENTS INFORMATION

7. CLINICAL TRIALS

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +